Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.
Identifieur interne : 000192 ( Main/Curation ); précédent : 000191; suivant : 000193Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.
Auteurs : Aliede E. In T Veld [Pays-Bas] ; Manon A A. Jansen [Pays-Bas] ; Luuk C A. Ciere [Pays-Bas] ; Matthijs Moerland [Pays-Bas]Source :
- Journal of immunology research [ 2314-7156 ] ; 2021.
Descripteurs français
- KwdFr :
- Antiviraux (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunosuppression thérapeutique (méthodes), Indice de gravité de la maladie (MeSH), Réplication virale (effets des médicaments et des substances chimiques), Résultat thérapeutique (MeSH), Transduction du signal (effets des médicaments et des substances chimiques).
- MESH :
- effets des médicaments et des substances chimiques : Réplication virale, Transduction du signal.
- méthodes : Immunosuppression thérapeutique.
- usage thérapeutique : Antiviraux, Hydroxychloroquine.
- Humains, Indice de gravité de la maladie, Résultat thérapeutique.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), COVID-19 (drug therapy), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunosuppression (methods), SARS-CoV-2 (drug effects), SARS-CoV-2 (immunology), Severity of Illness Index (MeSH), Signal Transduction (drug effects), Treatment Outcome (MeSH), Virus Replication (drug effects).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Hydroxychloroquine.
- drug effects : SARS-CoV-2, Signal Transduction, Virus Replication.
- drug therapy : COVID-19.
- immunology : SARS-CoV-2.
- methods : Immunosuppression.
- Humans, Severity of Illness Index, Treatment Outcome.
Abstract
The main basis for hydroxychloroquine (HCQ) treatment in COVID-19 is the compound's ability to inhibit viral replication in vitro. HCQ also suppresses immunity, mainly by interference in TLR signalling, but reliable clinical data on the extent and nature of HCQ-induced immunosuppression are lacking. Here, we discuss the mechanistic basis for the use of HCQ against SARS-CoV-2 in a prophylactic setting and in a therapeutic setting, at different stages of the disease. We argue that the clinical effect of prophylactic or therapeutic HCQ treatment in COVID-19 depends on the balance between inhibition of viral replication, immunosuppression, and off-target side effects, and that the outcome is probably dependent on disease stage and disease severity. This is supported by the initial outcomes of the well-designed randomized controlled trials: so far, evidence for a beneficial effect of HCQ treatment for COVID-19 is weak and conflicting.
DOI: 10.1155/2021/6659410
PubMed: 33763494
PubMed Central: PMC7949870
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000192
Links to Exploration step
pubmed:33763494Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.</title><author><name sortKey="In T Veld, Aliede E" sort="In T Veld, Aliede E" uniqKey="In T Veld A" first="Aliede E" last="In T Veld">Aliede E. In T Veld</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Leiden University Medical Center, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Jansen, Manon A A" sort="Jansen, Manon A A" uniqKey="Jansen M" first="Manon A A" last="Jansen">Manon A A. Jansen</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Ciere, Luuk C A" sort="Ciere, Luuk C A" uniqKey="Ciere L" first="Luuk C A" last="Ciere">Luuk C A. Ciere</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Moerland, Matthijs" sort="Moerland, Matthijs" uniqKey="Moerland M" first="Matthijs" last="Moerland">Matthijs Moerland</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Leiden University Medical Center, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33763494</idno><idno type="pmid">33763494</idno><idno type="doi">10.1155/2021/6659410</idno><idno type="pmc">PMC7949870</idno><idno type="wicri:Area/Main/Corpus">000192</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000192</idno><idno type="wicri:Area/Main/Curation">000192</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000192</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.</title><author><name sortKey="In T Veld, Aliede E" sort="In T Veld, Aliede E" uniqKey="In T Veld A" first="Aliede E" last="In T Veld">Aliede E. In T Veld</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Leiden University Medical Center, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Jansen, Manon A A" sort="Jansen, Manon A A" uniqKey="Jansen M" first="Manon A A" last="Jansen">Manon A A. Jansen</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Ciere, Luuk C A" sort="Ciere, Luuk C A" uniqKey="Ciere L" first="Luuk C A" last="Ciere">Luuk C A. Ciere</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Moerland, Matthijs" sort="Moerland, Matthijs" uniqKey="Moerland M" first="Matthijs" last="Moerland">Matthijs Moerland</name><affiliation wicri:level="1"><nlm:affiliation>Centre of Human Drug Research, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre of Human Drug Research, Leiden</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Leiden University Medical Center, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of immunology research</title><idno type="eISSN">2314-7156</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunosuppression (methods)</term><term>SARS-CoV-2 (drug effects)</term><term>SARS-CoV-2 (immunology)</term><term>Severity of Illness Index (MeSH)</term><term>Signal Transduction (drug effects)</term><term>Treatment Outcome (MeSH)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunosuppression thérapeutique (méthodes)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Réplication virale (effets des médicaments et des substances chimiques)</term><term>Résultat thérapeutique (MeSH)</term><term>Transduction du signal (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term><term>Signal Transduction</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Réplication virale</term><term>Transduction du signal</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunosuppression</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Immunosuppression thérapeutique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Indice de gravité de la maladie</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The main basis for hydroxychloroquine (HCQ) treatment in COVID-19 is the compound's ability to inhibit viral replication <i>in vitro</i>. HCQ also suppresses immunity, mainly by interference in TLR signalling, but reliable clinical data on the extent and nature of HCQ-induced immunosuppression are lacking. Here, we discuss the mechanistic basis for the use of HCQ against SARS-CoV-2 in a prophylactic setting and in a therapeutic setting, at different stages of the disease. We argue that the clinical effect of prophylactic or therapeutic HCQ treatment in COVID-19 depends on the balance between inhibition of viral replication, immunosuppression, and off-target side effects, and that the outcome is probably dependent on disease stage and disease severity. This is supported by the initial outcomes of the well-designed randomized controlled trials: so far, evidence for a beneficial effect of HCQ treatment for COVID-19 is weak and conflicting.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33763494</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2021</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.</ArticleTitle><Pagination><MedlinePgn>6659410</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/6659410</ELocationID><Abstract><AbstractText>The main basis for hydroxychloroquine (HCQ) treatment in COVID-19 is the compound's ability to inhibit viral replication <i>in vitro</i>. HCQ also suppresses immunity, mainly by interference in TLR signalling, but reliable clinical data on the extent and nature of HCQ-induced immunosuppression are lacking. Here, we discuss the mechanistic basis for the use of HCQ against SARS-CoV-2 in a prophylactic setting and in a therapeutic setting, at different stages of the disease. We argue that the clinical effect of prophylactic or therapeutic HCQ treatment in COVID-19 depends on the balance between inhibition of viral replication, immunosuppression, and off-target side effects, and that the outcome is probably dependent on disease stage and disease severity. This is supported by the initial outcomes of the well-designed randomized controlled trials: so far, evidence for a beneficial effect of HCQ treatment for COVID-19 is weak and conflicting.</AbstractText><CopyrightInformation>Copyright © 2021 Aliede E. in ‘t Veld et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>In 't Veld</LastName><ForeName>Aliede E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6927-397X</Identifier><AffiliationInfo><Affiliation>Centre of Human Drug Research, Leiden, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Manon A A</ForeName><Initials>MAA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9207-1807</Identifier><AffiliationInfo><Affiliation>Centre of Human Drug Research, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciere</LastName><ForeName>Luuk C A</ForeName><Initials>LCA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-2886-4540</Identifier><AffiliationInfo><Affiliation>Centre of Human Drug Research, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moerland</LastName><ForeName>Matthijs</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8064-8426</Identifier><AffiliationInfo><Affiliation>Centre of Human Drug Research, Leiden, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that there is no conflict of interest regarding the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>02</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33763494</ArticleId><ArticleId IdType="doi">10.1155/2021/6659410</ArticleId><ArticleId IdType="pmc">PMC7949870</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Infect Dis. 2021 Feb;103:1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">33075529</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation><ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ther. 2020 Nov/Dec;27(6):e573-e583</Citation><ArticleIdList><ArticleId IdType="pubmed">33136577</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Microbiol. 2020 Dec;51(4):1765-1769</Citation><ArticleIdList><ArticleId IdType="pubmed">33111169</ArticleId></ArticleIdList></Reference><Reference><Citation>Immun Inflamm Dis. 2021 Mar;9(1):31-36</Citation><ArticleIdList><ArticleId IdType="pubmed">33244901</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Microbiol Biotechnol. 2021 Feb;105(4):1333-1343</Citation><ArticleIdList><ArticleId IdType="pubmed">33515285</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invest Dermatol. 2019 Feb;139(2):324-332</Citation><ArticleIdList><ArticleId IdType="pubmed">30227141</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">32105090</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Intern Med. 2020 Dec;82:38-47</Citation><ArticleIdList><ArticleId IdType="pubmed">32859477</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2020 May 11;221(11):1762-1769</Citation><ArticleIdList><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2008 Dec;4(12):e1000240</Citation><ArticleIdList><ArticleId IdType="pubmed">19079579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2016 Feb 10;19(2):181-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Cardiol. 2014 Dec;30(12):1706-15</Citation><ArticleIdList><ArticleId IdType="pubmed">25475472</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents</Citation><ArticleIdList><ArticleId IdType="pubmed">11585785</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2021 Feb;103:599-606</Citation><ArticleIdList><ArticleId IdType="pubmed">33316389</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105960</Citation><ArticleIdList><ArticleId IdType="pubmed">32251731</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2015 May 26;6(3):e00638-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26015500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Rheumatol. 2010 Jan;16(1):28-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20051753</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2014 Sep 25;5:461</Citation><ArticleIdList><ArticleId IdType="pubmed">25309543</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2000 Jun 1;95(11):3460-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10828029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2020 Jun;20(6):343-344</Citation><ArticleIdList><ArticleId IdType="pubmed">32327719</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Apr 15;186(8):4794-804</Citation><ArticleIdList><ArticleId IdType="pubmed">21398612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Feb 07;7:42191</Citation><ArticleIdList><ArticleId IdType="pubmed">28169350</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinics (Sao Paulo). 2013 Jun;68(6):766-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23778483</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2020 Jun 16;52(6):910-941</Citation><ArticleIdList><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>JCI Insight. 2020 May 21;5(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">32324595</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rev Allergy Immunol. 2012 Apr;42(2):145-53</Citation><ArticleIdList><ArticleId IdType="pubmed">21221847</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2018 Oct;195:1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">29981383</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 25;382(26):2582</Citation><ArticleIdList><ArticleId IdType="pubmed">32501665</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2019 Feb 21;10:275</Citation><ArticleIdList><ArticleId IdType="pubmed">30846987</ArticleId></ArticleIdList></Reference><Reference><Citation>Allergy. 2020 Jul;75(7):1564-1581</Citation><ArticleIdList><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Rheumatol. 2020 Nov;2(11):e689-e697</Citation><ArticleIdList><ArticleId IdType="pubmed">32984847</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2021 Jan;27(1):19-27</Citation><ArticleIdList><ArticleId IdType="pubmed">32860962</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2016 Aug;14(8):523-34</Citation><ArticleIdList><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2007 Jul;46(7):1157-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17478469</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Dec;101:283-289</Citation><ArticleIdList><ArticleId IdType="pubmed">33007454</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2006 Feb;54(2):628-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16447241</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Forum Infect Dis. 2020 Sep 23;7(10):ofaa446</Citation><ArticleIdList><ArticleId IdType="pubmed">33134417</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2021 Feb 1;181(2):195-202</Citation><ArticleIdList><ArticleId IdType="pubmed">33001138</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2020 Jan 1;59(1):107-111</Citation><ArticleIdList><ArticleId IdType="pubmed">31237947</ArticleId></ArticleIdList></Reference><Reference><Citation>J Investig Dermatol Symp Proc. 2017 Oct;18(2):S57-S63</Citation><ArticleIdList><ArticleId IdType="pubmed">28941496</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacology. 2000 May;47(2-3):215-45</Citation><ArticleIdList><ArticleId IdType="pubmed">10878291</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Jun 9;323(22):2249-2251</Citation><ArticleIdList><ArticleId IdType="pubmed">32374370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 May 28;181(5):1036-1045.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Drug Investig. 2020 Jul;40(7):591-601</Citation><ArticleIdList><ArticleId IdType="pubmed">32468425</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Jun 13;395(10240):1820</Citation><ArticleIdList><ArticleId IdType="pubmed">32511943</ArticleId></ArticleIdList></Reference><Reference><Citation>J Allergy Clin Immunol. 2013 May;131(5):1443-6.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">23541328</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Res Ther. 2012 Jun 27;14(3):R155</Citation><ArticleIdList><ArticleId IdType="pubmed">22734582</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Res Ther. 2017 Aug 9;19(1):183</Citation><ArticleIdList><ArticleId IdType="pubmed">28793932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2017 Oct;76(10):1755-1763</Citation><ArticleIdList><ArticleId IdType="pubmed">28760805</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Jul;583(7816):437-440</Citation><ArticleIdList><ArticleId IdType="pubmed">32434211</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000192 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000192 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:33763494
|texte= Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:33763494" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |